Phase II Open Label, Multi-Center Clinical Trial Of Modulation Of Intermediate Endpoint Biomarkers By 1x-Hydroxyvitamin D2 In Patients With Clinically Localized Prostate Cancer And High Grade PIN
Phase of Trial: Phase II
Latest Information Update: 13 Oct 2016
At a glance
- Drugs Doxercalciferol (Primary)
- Indications Prostate cancer
- Focus Adverse reactions; Biomarker; Pharmacodynamics
- 10 Oct 2016 Status changed from active, no longer recruiting to completed.
- 04 Oct 2005 New trial record.